Carbidopa/oxytriptan - Evecxia
Alternative Names: EVX-101Latest Information Update: 28 Oct 2025
At a glance
- Originator Evecxia
- Class Antidepressants; Behavioural disorder therapies; Catecholamines; Hydrazines; Small molecules; Tryptamines
- Mechanism of Action Decarboxylase inhibitors; Serotonin modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obsessive-compulsive disorders
- No development reported Depressive disorders
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in United Kingdom (PO, Controlled release)
- 22 Sep 2025 Evecxia plans a proof of concept phase II study for Obsessive-compulsive disorders in 1H 2026 (PO, tablet)
- 22 Sep 2025 Evecxia plans a small bridging phase I pharmacokinetics (PK) study in healthy volunteers in the second half of 2025 (PO, tablet)